Press releases04.04.24 MHRA grants Promising Innovative Medicine designation to Camallergy’s peanut allergy treatment29.11.23 Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment30.01.23 Camallergy wins £2m additional funding through second Innovate UK Biomedical Catalyst award01.07.22 FDA accepts Camallergy's phase 3 IND for "CA002" novel treatment for peanut allergy23.03.21 Camallergy awarded £1.1m funding under Innovate UK Biomedical Catalyst Award for novel peanut allergy treatment 08.01.21 Camallergy’s UK-based manufacturing facility receives cGMP licences for peanut allergy treatment07.10.20 Camallergy’s Chief Medical Officer receives distinguished award from British Allergy SocietyNews Subscribe
